This is consistent with accruing evidence of the tumor-promoting roles of components of the multi-protein Mediator complex, including reports that Mediator subunit CDK19 is specifically expressed in prostate cancer, with upregulated expression being associated with disease progression, as observed in patients with metastatic and castration-resistant disease (28). Here, CDK19 is linked to neoplasm.